Health Economics›Plasma cell leukemia›First-line therapy

First-line therapy

Plasma cell leukemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
PAD/VCD Variant #01	—	R 19 260	21d	—	—	~4	~R 52 738 indirect	—
Lenalidomide and Dexamethasone (Rd) Variant #02	—	R 4 309	28d	~21.0 mo	~55.4 mo	~40	~R 132 764 PFS proxy · indirect	27

2 of 2 regimens shown